Nestlé Acquires Peanut Allergy Treatment Maker, Aimmune Therapeutics
Nestlé has announced that it has completed the acquisition of Aimmune Therapeutics, Inc., the maker of peanut allergy treatment, Palforzia.
Aimmune Therapeutics will be a part of Nestlé Health Science (NHSc) as a stand-alone business unit and continue to operate from Brisbane, California.
In August of this year, Nestlé offered $2 billion (€1.7 billion) to gain full ownership of the California-based biopharmaceutical company.
ESM
Related news
Nestlé invests in speciality protein-foods factory in Germany
The site in Rosbach vor der Höhe houses Nestlé’s Vitaflo…
Read more >Another successful trade fair presence by the Future Store
Trade magazin, the official journal of SIRHA Budapest 2024 was…
Read more >Nestlé Launches Website To Support People On Weight-Loss Drugs
Food giant Nestlé’s health unit has launched a web platform…
Read more >Related news
VOSZ Barometer – 2024. II. quarter: mandatory optimism or real growth?
The perception of inflation is still present in domestic companies,…
Read more >Fidelity: Three themes shaping investments in Q3
Has the post-epidemic normalization that we have been waiting for…
Read more >Auchan has appointed a new product director
From July 1, László Varga will perform the duties of…
Read more >